Cardiovascular and Metabolic Health
What we do
Cardiovascular and metabolic disease presents a tremendous, and increasing, health and economic burden for individuals and society worldwide. MIPS, home to more than 450 scientists, has a growing emphasis on multidiscipline cutting edge cardiometabolic research to address these global challenges.
MIPS expertise in Cardiovascular and Metabolic Health encompasses medicinal chemistry, structural biology, analytical pharmacology, drug disposition, drug delivery, translational models of disease and medicines use and safety. Our commitment to research translation is evidenced by contributing to more than 30 novel drug candidates into clinical development.
We have particular skills in:
the pharmacology of G protein-coupled receptors and the role of allostery and biased signalling in receptor pharmacology
structure-based drug design and the use of fragment-based screening in drug discovery
identification of optimal pharmaceutical properties for drug molecules during hit-to-lead and lead optimisation through to candidate selection
oral and pulmonary drug delivery and the use of nanomedicines in optimised drug therapy
cellular and animal physiology of cardiovascular and metabolic disease models
pharmacoepidemiology and pharmacometrics
Cardiovascular research View
Cardiovascular research programs have a focus on delineating the underpinning mechanisms and developing new treatments for heart failure, diabetic cardiomyopathy and cardiopulmonary diseases.
Metabolic research View
Metabolic research programs focus on understanding how excess nutrient consumption and nonfunctioning metabolic organs contribute to obesity, diabetes and metabolic associated cancers, thus enabling the development of improved treatments for metabolic associated diseases.